OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bunn on Initial Results of the MYSTIC Trial in Stage IV Lung Cancer

July 28th 2017

Paul A. Bunn, MD, distinguished professor, Division of Medical Oncology, and James Dudley Chair in Lung Cancer Research, University of Colorado, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.

Dr. Cohen on Immunotherapy in Head and Neck Squamous Cell Carcinoma

July 27th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy in head and neck squamous cell carcinoma.

The Future of MRI in Prostate Cancer

July 27th 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses the future of MRI in prostate cancer.

Dr. Pavlick on Adjuvant Immunotherapy in High-risk Melanoma

July 27th 2017

Anna C. Pavlick, DO, associate professor of hematology and medical oncology and medical director of the Clinical Trials Office at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the need for adjuvant immunotherapy in patients with high-risk melanoma.

Dr. Wilson on Long-term Data With Dabrafenib Plus Trametinib in Melanoma

July 27th 2017

Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses the long-term data with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF-mutant melanoma.

Dr. Atkins on Excitement With Atezolizumab and Bevacizumab in RCC

July 27th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the excitement surrounding the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma (RCC).

Dr. Plimack on Combo of Pembrolizumab/Epacodostat in Bladder Cancer

July 27th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the phase Ib trial of epacodostat and pembrolizumab (Keytruda) in patients with urothelial carcinoma.

Dr. Bauml on CAR T-Cell Therapy in Head and Neck Cancer

July 27th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses CAR T-cell therapy in head and neck cancer.

Dr. Burtness on Immunotherapy Resistance in Head and Neck Cancer

July 27th 2017

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses immunotherapy resistance in head and neck cancer.

Dr. Choueiri on Synergy Between Immunotherapy and VEGF Inhibitors in RCC

July 26th 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the synergy between immunotherapy agents and VEGF inhibitors in renal cell carcinoma (RCC).

Dr. Garcia on Selecting Second-line Immunotherapy in Bladder Cancer

July 26th 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses selecting a second-line and beyond immunotherapy treatment for patients with bladder cancer.

Dr. Bauml on Next Steps for Immunotherapy in Head and Neck Cancer

July 25th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the next steps for immunotherapy in head and neck cancer.

Dr. Weiss on Immunotherapy Combinations in Head and Neck Cancer

July 25th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.

Dr. Cohen Discusses NK-Directed Therapy in Head and Neck Cancer

July 25th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses natural killer-directed therapy in head and neck cancer.

Dr. Chi Discusses the LATITUDE Study in Metastatic Prostate Cancer

July 25th 2017

Kim Chi, MD, associate director of clinical research, Vancouver Prostate Centre, professor, Department of Medicine, University of British Columbia, discusses the LATITUDE study in metastatic prostate cancer.

Dr. Ornstein on Role of IL-2 in Patients With RCC

July 24th 2017

Moshe Ornstein, MD, staff, Cleveland Clinic, discusses the role of interleukin-2 (IL-2) going forward in patients with renal cell carcinoma (RCC).

Dr. Shah on Emerging Developments in MCL

July 24th 2017

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses some of the emerging developments on the horizon in mantle cell lymphoma (MCL).

Dr. Balar on Combinations with Pembrolizumab for Urothelial Cancer

July 21st 2017

Arjun V. Balar, MD, assistant professor of Medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Dr. Sartor on Remaining Questions With Sipuleucel-T in mCRPC

July 21st 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the remaining questions with sipuleucel-T (Provenge) in metastatic castration-resistant prostate cancer.

Dr. Black Discusses the Impact of Durvalumab in Bladder Cancer

July 21st 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses the impact of durvalumab (Imfinzi) in bladder cancer.